| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 药品销售(元) | 88,195,829.06 | 150,176,522.86 | 71,309,008.68 | 113,014,495.29 | 50,092,435.15 |
| 医药中间体销售(元) | - | 17,321,543.08 | 11,053,482.89 | 11,901,124.80 | 1,667,068.13 |
| 受托加工销售(元) | - | 116,669.73 | 95,040.00 | 170,072.92 | - |
| 技术开发/转让(元) | 4,300,000.00 | 6,800,000.00 | - | - | - |
| 受托加工业务(元) | 66,487.86 | - | - | - | - |
| 营业成本(元) | |||||
| 药品销售(元) | 19,698,927.84 | 32,548,935.83 | 15,624,951.93 | 25,059,656.86 | 11,255,968.05 |
| 医药中间体销售(元) | - | 15,649,805.87 | 9,227,549.44 | 10,201,409.52 | 1,394,402.47 |
| 受托加工销售(元) | - | 166,991.67 | 87,996.65 | 149,034.82 | - |
| 技术开发/转让(元) | 11,616.89 | - | - | - | - |
| 受托加工业务(元) | 138,813.60 | - | - | - | - |
| 毛利(元) | |||||
| 药品销售(元) | 68,496,901.22 | 117,627,587.03 | 55,684,056.75 | 87,954,838.43 | 38,836,467.10 |
| 医药中间体销售(元) | - | 1,671,737.21 | 1,825,933.45 | 1,699,715.28 | 272,665.66 |
| 受托加工销售(元) | - | -50,321.94 | 7,043.35 | 21,038.10 | - |
| 技术开发/转让(元) | 4,288,383.11 | 6,800,000.00 | - | - | - |
| 受托加工业务(元) | -72,325.74 | - | - | - | - |
| 毛利率(%) | |||||
| 药品销售(%) | 77.66 | 78.33 | 78.09 | 77.83 | 77.53 |
| 医药中间体销售(%) | - | 9.65 | 16.52 | 14.28 | 16.36 |
| 受托加工销售(%) | - | -43.13 | 7.41 | 12.37 | - |
| 技术开发/转让(%) | 99.73 | - | - | - | - |
| 受托加工业务(%) | -108.78 | - | - | - | - |
| 收入构成(%) | |||||
| 药品销售(%) | 95.28 | 86.10 | 86.48 | 90.35 | 96.78 |
| 医药中间体销售(%) | - | 9.93 | 13.41 | 9.51 | 3.22 |
| 受托加工销售(%) | - | 0.07 | 0.12 | 0.14 | - |
| 技术开发/转让(%) | 4.65 | 3.90 | - | - | - |
| 受托加工业务(%) | 0.07 | - | - | - | - |
| 毛利构成(%) | |||||
| 药品销售(%) | 94.20 | 93.32 | 96.81 | 98.08 | 99.30 |
| 医药中间体销售(%) | - | 1.33 | 3.17 | 1.90 | 0.70 |
| 受托加工销售(%) | - | -0.04 | 0.01 | 0.02 | - |
| 技术开发/转让(%) | 5.90 | 5.39 | - | - | - |
| 受托加工业务(%) | -0.10 | - | - | - | - |